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withdrawn from publication by the FDA as a result of lobbying by
Medtronic.1 According to the Wall Street Journal, this article
“raised concerns about the long term safety record of a device”
which was the subject of a Public Health Notification (PHN) by
the FDA in December 2003.2 We regret that the article will not be
published for it would provide an opportunity to examine evidence
upon which clinical practice decisions may be based. We hope that
this letter will provide information on the long-term safety of the
AneuRx stent graft that can be weighed against the FDA PHN and
media interpretations.
In the PHN, the FDA reported its analysis of 942 patients
treated with the AneuRx stent graft and found a 30-day abdominal
aortic aneurysm (AAA) death rate of 1.5%, with 8 late AAA deaths
during 3 follow-up years. The cumulative AAA death rate was 2.7%
at 3 years,2 which was lower than the 3.1% AAA death rate reported
for all 1193 patients treated during the AneuRx clinical trial,3 due
to exclusion of high-risk patients from the FDA analysis. It was also
lower than the 3% to 5% operative mortality for surgery, which the
FDA found in the literature.2 However, rather than reassuring
patients with these good results, the FDA suggested that “the risk
of late AAA-related mortality associated with AneuRx may exceed
that associated with open surgery [and] the overall AAA-associ-
ated mortality from the AneuRx Stent Graft is likely to cross-over
and exceed the AAA-associated mortality from open surgery at
some point in time.”2 How could the FDA arrive at this remarkable
conclusion? Perhaps the supporting data appear in the “squelched”
article, and these needs to be published.
From our reading of the PHN, it appears the FDA assumed
that operative mortality for surgery is 1% to 2%, that late AAA death
rate is 0.18% per year (as opposed to 0.4% per year for AneuRx),
and that late adverse events for both increase linearly with time. We
find little data to support these assumptions. There is, however,
actual data with Kaplan-Meier analysis extending to 5 years for all
1193 AneuRx clinical trial patients.4 How do the FDA’s projec-
tions compare to these actual data? Since the FDA excluded
high-risk patients, we excluded the 262 high-risk patients in the
trial, leaving 931 patients, very similar to the 942 patients studied
by the FDA. The AAA death rates for these 931 patients at 30 days
and 1 to 5 years are as follows: 1.5%, 1.5%, 1.8%, 1.9%, 2.5%, and
2.5% (Kaplan-Meier analysis). Thus far, there have been no AAA
deaths beyond 4 years, suggesting that AAA death for AneuRx
patients does not increase linearly with time. Using the FDA’s
estimate of 0.18% per year, and assuming operative mortality rates
of 2% and 5% at 5 years, the AAA death rate for surgery would be
2.9% and 5.9%, both higher than the actual 2.5% 5-year AAA death
rate for AneuRx. Thus, evidence for a late “cross-over” of results is
lacking.
We call for publication of the article containing the evidence
upon which the FDA has made practice-based recommendations
in its PHN so that patients and physicians can judge the evidence
and select the best treatment option.
Christopher K. Zarins
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Regarding “Carotid endarterectomy in SAPPHIRE-
eligible high-risk patients: Implications for selecting
patients for carotid angioplasty and stenting”
A recent article by Mozes and associates (J Vasc Surg 2004;
39:958-965) seeks to compare 2 groups of patients who under-
went carotid endarterectomy at a single institution over a 5-year
period. These 2 groups were defined as high risk and low risk,
ostensibly on the basis of the eligibility criteria of the high-risk
SAPPHIRE randomized trial of stenting versus endarterectomy.
The reference that the authors quote, however, is not from the
SAPPHIRE trial. Rather, the high-risk criteria were extracted from
an article by Jordan and colleagues.1
That aside, the authors aptly concluded that endarterectomy
can be performed in high-risk patients with acceptable risks of
stroke and death. The question of whether carotid stenting should
be considered in such high-risk patients, however, cannot be
resolved by a comparison of outcome in high- and low-risk pa-
tients. Rather, this question is best answered through a random-
ized comparison of stenting and endarterectomy, either in lower-
risk patients (eg, the CREST trial) or higher-risk patients (eg,
SAPPHIRE).
The authors reasoned that similar results with endarterectomy
in high-risk versus lower-risk patients raise questions about the
appropriateness of stenting as an alternative to endarterectomy.
But the authors’ own data document a mortality rate of 0.6% in
high-risk patients versus 0.0% in low-risk patients (P  .11, calcu-
lated with the 2 test and from their data). When the high-risk
subgroups were compared with lower-risk subgroups, the stroke
rate was 1.9% versus 1.1% (P .45), the frequency of perioperative
myocardial infarction was 3.1% versus 0.9% (P .03), and the rate
of the composite stroke and death myocardial infarction was 9.3%
versus 1.6% (P .000001). For each end point, the point estimates
were higher in the high-risk patients. While some end points did
not achieve statistical superiority, the failure to detect statistical
superiority does not exclude an end point with conviction. Said
another way, the P value of .11 suggests that we are “only” 89%
certain that the mortality rate was greater in the high-risk patients.
Although the SAPPHIRE data have not yet appeared in the
literature, the data presented to the Food and Drug Administra-
tion panel this April suggested that the results of stenting were
equivalent or superior to endarterectomy.2 The demonstration of
non-inferiority of stenting is all that will be required for patients to
preferentially choose a procedure that avoids a neck incision.
Vascular surgeons appear best-equipped to care for patients
with carotid disease: they understand the anatomy, the indications
for intervention, and the necessity for long-term follow-up. We can
choose to become proficient at carotid stenting and be able to offer
it as one potential treatment option. Alternatively, we can discount
this new modality, but we will risk relinquishing the responsibility
for carotid diagnosis and treatment to other specialty groups who
may be unaccustomed to caring for patients with cerebrovascular
disease.
Kenneth Ouriel, MD
The Cleveland Clinic Foundation
Cleveland, Ohio
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Reply
I appreciate the opportunity to respond to Dr Ouriel’s reflec-
tions regarding our article documenting the carotid endarterec-
tomy experience from the Division of Vascular Surgery, Mayo
Clinic, Rochester, Minn. The purpose of this study was to examine
the implications of high-risk criteria (as defined by the Food and
Drug Administration–approved, industry-sponsored SAPPHIRE
study) on outcomes following carotid endarterectomy (CEA). It is
our perception that these criteria are overly inclusive, that they
envelope a group of patients on whom we frequently operate, and
that the endarterectomy results from SAPPHIRE are inferior to
those achieved in our own practice (and likely in many other
centers of excellence). In our retrospective study in 776 consecu-
tive patients, we found no difference in the individual end points of
death, stroke, or myocardial infarction (MI) when comparing
high- and low-risk groups. The combined end point of death,
stroke, and MI did reach significance (P  .05) when comparing
high- and low-risk symptomatic patients, but not asymptomatic
patients. In addition, we identified only 4 factors predictive of
perioperative stroke: cervical radiation therapy, class III/IV an-
gina, age 60 years and, to a lesser degree, symptomatic presen-
tation. The high-risk patients in our series were, in fact, comparable
to those in SAPPHIRE, as defined in Tables I-III. Although these
tables faithfully reproduce the SAPPHIRE criteria, they are incor-
rectly referenced within the text; we appreciate Dr Ouriel’s bring-
ing this typographic error to our attention.
Dr Ouriel correctly points out that statistical analyses are
sometimes flawed or misinterpreted; to quote Mark Twain, “There
are lies, damn lies, and statistics.” Nevertheless, our practices,
especially as they relate to cerebrovascular disease—and particu-
larly in asymptomatic patients, where margins of efficacy are thin—
are typically guided by evidenced-based medicine and determined
by rigid analysis of peer-reviewed data, not by trends, perceptions,
or industry hype. These methods of exacting analysis have been
applied to the SAPPHIRE data set (which has not yet been
published or subject to peer review), demonstrating equivalency of
carotid angioplasty/stenting (CAS) to endarterectomy in high-risk
patients; these data will hopefully be used to achieve Food and
Drug Administration approval. As such, we stand by our conclu-
sions, as stated in the article, which are based on currently accepted
statistical analysis. In addition, while the composite end point of
stroke, death, and MI in our study was statistically different in
symptomatic patients, this difference was largely driven by the
occurrence of non-Q MI, much like SAPPHIRE. While “myocar-
dial enzyme leak” is clearly not a positive outcome, its significance
remains uncertain. Depending on the sensitivity of the biomarker
used, nearly 40% of patients having percutaneous coronary inter-
vention suffer this complication, and although these patients are at
increased risk of subsequent cardiac death, a cause-and-effect
relationship remains to be determined. Biomarker release follow-
ing coronary angioplasty, carotid endarterectomy, or CAS may
simply identify a group of patients already at risk for future coro-
nary events.1,2
With respect to Dr Ouriel’s final point, we could not be in
better agreement—vascular surgeons represent the group of phy-
sicians best able to manage patients with carotid artery disease. I
have personally been involved with carotid angiography and inter-
vention for nearly a decade, and remain active in clinical trials of
CAS. I have trained many of my vascular surgical colleagues and
have encouraged them to become proficient in these techniques so
that we, as a specialty, can remain at the forefront. It is imperative
that we take a leading role in carotid intervention, lest we become
a historical footnote.3 Perhaps, however, we see our respective
roles differently; I believe that it is my obligation to counsel
patients as to the risks, benefits, and long-term outcomes of all
available therapies (medical, interventional, and surgical) that re-
late to their particular disease, and to make a recommendation to
that specific individual on the basis of the available peer-reviewed
literature and the results of procedures performed within my own
institution.4 I will have neglected my duty by simply performing
the procedure “that the patient wants”—the one that “avoids a
neck incision” or is currently in vogue. While CAS may ultimately
become first-line therapy, carotid endarterectomy remains the
treatment of choice for the vast majority of patients with high-
grade carotid artery stenosis in our practice; further prospective,
randomized studies will hopefully further define the role of CAS in
both high-risk and low-risk patients.
Timothy M. Sullivan, MD
Mayo Clinic
Rochester, Minn
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